Results 101 to 110 of about 589,499 (392)
European Journal of Endocrinology, 2012 OBJECTIVE Dopamine agonists normalize prolactin (PRL) levels and reduce tumour size in responsive prolactinoma. However, several cases have shown resistance to dopamine agonists upon initial treatment.
Satoko Shimazu +6 more
semanticscholar +1 more source
Dopamine agonists and Othello’s syndrome [PDF]
Parkinsonism & Related Disorders, 2010 Othello's syndrome (OS) is a delusion of infidelity. We describe seven cases of OS in Parkinson's disease (iPD) patients using dopamine agonists.We searched the Mayo Clinic Medical Records System to identify all patients with OS. Clinical data abstracted include sex, age of onset of iPD, age of onset of OS, medications, effect of discontinuing the ...
James H. Bower +3 more
openaire +3 more sources
Pharmacology of novel psychoactive substances [PDF]
, 2016 This PhD work consists of an in vitro and in vivo part. In the in vivo part, we investigated the role of dopamine in the acute clinical effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in healthy human subjects.
Rickli, Anna
core +1 more source
Frontiers in Neurology, 2018 Impulse control disorder (ICD), including pathological gambling, hypersexuality, and compulsive shopping has been linked to antiparkinsonian medication, especially dopamine agonists.
Pedro J. Garcia-Ruiz
doaj +1 more source
A normative theory of social conflict [PDF]
arXiv, 2023 Social hierarchy in animal groups carries a crucial adaptive function by reducing conflict and injury while protecting valuable group resources. Social hierarchy is dynamic and can be altered by social conflict, agonistic interactions, and aggression.
arxiv
Cerebral blood flow predicts differential neurotransmitter activity [PDF]
, 2018 Application of metabolic magnetic resonance imaging measures such as cerebral blood flow in translational medicine is limited by the unknown link of observed alterations to specific neurophysiological processes. In particular, the sensitivity of cerebral
Bertolino, A +24 more
core +6 more sources
Nature and Science of Sleep, 2023 Elliott Kyung Lee,1,2 Naomi Spitale,2,3 Rebecca Robillard2 1Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada; 2Sleep Research Unit, Institute for Mental Health Research (IMHR), Ottawa, Ontario, Canada; 3Department of Medicine ...
Lee EK, Spitale N, Robillard R
doaj
D₂ Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways [PDF]
, 2005 Regulator of G-protein signaling 9-2 (RGS9-2), a member of the RGS family of Gα GTPase accelerating proteins, is expressed specifically in the striatum, which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia. We
Axelrod, Jeffrey D. +10 more
core
The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]
, 2016 Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea +3 more
core +2 more sources
Parkinson's Disease, 2012 Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments for PD focus on dopaminergic therapies, including L-dopa and dopamine receptor agonists.
Carina J. Bleickardt +3 more
doaj +1 more source